

WeedMD Inc

11:36 13 Feb 2020

WeedMD subsidiary Starseed Medicinal awarded cannabis research license

WeedMD Inc (CVE:WMD) (OTCMKTS:WDDMF) subsidiary Starseed Medicinal Inc received its cannabis research license from Health Canada, the company announced Thursday.

The license allows the Toronto-based medical marijuana firm to test cannabis concentrates that pertain to vape products in development testing at its Bowmanville, Ontario facility.

WeedMD CEO Angelo Tsebelis told shareholders that the company was committed to developing new cannabis products for its customers.

READ: WeedMD subsidiary Starseed Medicinal adds benefits provider myHSA to its medical cannabis program

"With the evolution of next-generation cannabis products such as extracts for vaporization, we want to ensure we drive important data collection forward on behalf of our patients and consumers," Tsebelis said in a statement.

"We are diligently assessing new cannabis products - in this case, specific to vapes - to determine optimum formulations that will result in the best performance and delivery of medical cannabis, as well as consumer acceptability."

According to WeedMD, the research license gives way to activities and protocols that involve direct handling and storage of cannabis while also allowing for the administration and distribution of cannabis to focus group subjects for feedback. The program is also expected to evaluate the effect of storage conditions on vape cartridges to ensure product stability over time.

WeedMD acquired Starseed Holdings in December 2019.

The firm also said that as part of the acquisition it was granting nearly 5.7 million options at C\$0.98 per share expiring November 3, 2022, and just over 900,000 WeedMD option with an exercise price of C\$3.26 per share expiring on November 1, 2023.

Contact Angela at angela@proactiveinvestors.com


Follow her on Twitter @AHarmantas

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Price: 0.58

Market Cap: \$121.55 m

1 Year Share Price Graph



May 2019 November 2019 May 2020

Share Information

Code: WMD

Listing: TSX-V

52 week	High	Low
	1.88	0.26

Sector: Cannabis

Website: www.weedmd.com

Company Synopsis:

WeedMD Inc. is the publicly-traded parent company of WeedMD Rx Inc. , a federally-licensed producer of cannabis products for both the medical and adult-use markets. The Company owns and operates a 158-acre state-of-the-art greenhouse, outdoor and processing facility located in Strathroy, Ontario. WeedMD also operates CX Industries Inc. , a wholly-owned subsidiary of WeedMD Inc.

action@proactiveinvestors.com

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of WeedMD Inc named herein, including the promotion by the Company of WeedMD Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).